Regeneron (REGN) Stock Analysis 2026: Dupixent COPD Approval at 18x PE Before April 29 Earnings

Regeneron is trading at 18x trailing earnings. So is Merck. The problem with that comparison is that Merck's lead drug (Keytruda) faces a patent cliff in 2028. Regeneron's lead drug (Dupixent) was just approved for chronic obstructive pulmonary disease in September 2024 — opening a potential $20 billion addressable market it hasn't touched yet.

The Equity Rank screener surfaces a 51% combined margin of safety on REGN at $746. The model's consensus fair value is $1,193 — a 60% premium to current price. Analyst consensus is more conservative at $875 (+17.4%), but still significantly above current levels.

The catch: EPS has declined 2.6% in the trailing twelve months and 13.6% over five years. If you screen REGN on backward-looking growth alone, it looks like a story ending. The data says something more specific is happening — and it's worth understanding before April 29 earnings.

Regeneron at a Glance (April 2026)

Data: Equity Rank screener and analysis cache (April 17, 2026).

Why EPS Is Declining (And Why It Matters Less Than You Think)

Regeneron's EPS peaked in 2021-2022 when Eylea — its VEGF inhibitor for age-related macular degeneration and diabetic macular edema — was generating peak revenue. Since mid-2023, biosimilar competition (Sandoz's Byooviz, Coherus's Cimerli, and others) plus share loss to Roche's Vabysmo has steadily compressed Eylea's revenue contribution.

That's the reason EPS is down -2.6% TTM and -13.6% over five years. It is not a story about the business deteriorating — it's a story about one franchise in decline (Eylea) being offset by another in ascent (Dupixent).

Dupixent 2024 revenue: approximately $14.1B globally (+21% YoY), making it one of the top-10 selling drugs in the world.

Dupixent's approved indications as of April 2026:

• Atopic dermatitis (eczema) — all ages
• Asthma — moderate to severe
• Chronic rhinosinusitis with nasal polyposis
• Eosinophilic esophagitis
• Prurigo nodularis
• COPD with type-2 inflammation — approved September 2024

The COPD approval is the story the valuation is not yet pricing. COPD affects approximately 16 million diagnosed Americans, and Dupixent's Phase 3 BOREAS and NOTUS trials showed meaningful FEV1 improvement and exacerbation reduction in the eosinophilic COPD subset (roughly 40% of patients). At $40,000+ per patient annually, even 2-5% market penetration in the addressable subset implies $5B+ in additional peak revenue.

Against that backdrop, a PE of 18x is the market saying: "We'll believe it when we see it."

Valuation: What 14 Methods Say About REGN at $746

The Equity Rank model runs 19 valuation methods against Regeneron using Biotechnology sector multiples (PE 35x, P/B 7x, P/S 9x, EV/EBITDA 28x):

Model consensus fair value: $1,193.56 (+37.5% MoS) Analyst consensus target: $875.45 (+17.4% MoS)

Why EPV, PEG, DDM, and Graham Are Negative — And What That Means

Four methods show negative margin of safety. Each has a specific reason:

Earnings Power Value (-91.7%): EPV values a business as a perpetuity on normalized after-tax operating income divided by WACC. Because REGN's operating income reflects the Eylea decline without crediting Dupixent's future growth, EPV captures a frozen-in-time view of current earnings power. It's the right tool for steady-state businesses — not for companies with a major franchise transition underway.

PEG (-135.7%): PEG = PE / EPS growth rate. With trailing 5-year EPS growth at -13.6%, the PEG formula produces a negative denominator, making fair value meaningless. If you substitute the Dupixent-driven forward growth rate (analysts estimate +12-15% EPS CAGR over 2025-2027 as COPD ramps), PEG fair value turns materially positive. The negative here is entirely an artifact of the Eylea decline period.

DDM (-244.4%): Regeneron pays a token dividend of $3.56 annually — essentially zero yield at 0.48%. DDM is the right model for AT&T or Verizon. For REGN, it produces a nonsense fair value because the company returns capital through buybacks, not dividends.

Graham Number (-40.8%): Graham's formula ($529 vs $746) reflects conservative book-value-based thinking. REGN's book value ($300/share) does not capture the economic value of the Dupixent franchise — a biological asset not fully recognized on the balance sheet. Biotech intellectual property is consistently undervalued by book-based methods.

The honest summary: the positive MoS methods (PE, P/S, EV/EBITDA) all say REGN is cheap relative to biotech peers. The negative MoS methods either can't handle negative growth inputs or ignore REGN's franchise value. Neither is wrong — they're answering different questions.

The Stability Story: Why Risk Score Is 26.5

REGN's Stability Score of 82.3 out of 100 is one of the highest in the screener for a company its size. The drivers:

• Current ratio 4.13: Exceptional liquidity buffer
• Net cash position: D/E of 0.065x means Regeneron has essentially zero financial leverage. Net debt per share is -$10.53 — the company has more cash than debt.
• Net margin 31.4%: Pharmaceutical margins at full commercial scale
• Merton distance-to-default: 53.3: Zero realistic probability of financial distress

The Risk Score of 26.5 (Low) reflects this fortress balance sheet combined with a Beta of 0.397 — meaning REGN moves at roughly 40% of the market's volatility. For a biotech stock, this is remarkably stable.

The primary risks are not financial — they're pipeline and competitive:

Eylea biosimilar acceleration: If market share loss accelerates beyond current pacing, Eylea revenue could fall faster than Dupixent COPD can offset. This is already priced in to some degree at $746.

COPD penetration risk: Dupixent's COPD label is limited to patients with eosinophilic inflammation markers (Type-2 biology). Actual addressable patients may be smaller than the headline COPD market implies. Patient identification and payer coverage remain commercialization challenges.

Competitive biologics: Astrazeneca's Fasenra and Glaxo's Nucala compete in the IL-5 pathway. Dupixent's IL-4/IL-13 mechanism is differentiated but not without alternatives.

R&D concentration: Dupixent now accounts for the majority of REGN's revenue. Pipeline diversification exists (Kevzara, Libtayo, antibody cocktails) but Dupixent is the franchise.

What April 29 Earnings Will Tell You

Revenue trend: Consensus estimates ~$3.6-3.7B quarterly revenue. The key watch is Dupixent global net product sales (Sanofi reports; REGN reports its share of profit). Any acceleration above 20% YoY global growth confirms the COPD ramp is beginning.

Eylea U.S. revenue: Watch for the rate of decline. If Eylea U.S. net revenue stabilizes above $350M quarterly, the Dupixent growth story can carry the company. If it falls below $300M, the offset math gets harder.

COPD early uptake signals: Analysts will ask specifically about COPD prescription volume, payer coverage rates, and market access. This is the first full quarter with meaningful COPD commercial infrastructure in place (approval was September 2024 — first two quarters were market access ramp).

EPS guidance: Forward EPS estimate is $40.39. If REGN guides 2026 EPS above $42-44, the growth-resumption thesis becomes credible and the 18x multiple looks historically cheap.

IV context: Current implied volatility is 24.6% with an options-implied earnings move of ±4.47% (~$33). At $746, that puts the implied post-earnings range at approximately $713–$779. The put/call ratio of 0.68 suggests options positioning is modestly more bullish than neutral.

The Core Question the Model Is Asking

The model's consensus fair value of $1,193 (37.5% MoS) and the analyst target of $875 (17.4% MoS) are both telling you the same thing: the current price is pricing in continued Eylea-driven EPS compression with no credit for Dupixent COPD upside.

If you believe:

• COPD penetration reaches 3-5% of addressable patients by 2028 ? +$3-5B revenue
• Dupixent continues expanding into 2-3 additional indications (COPD readouts for broader phenotypes, chronic spontaneous urticaria, and others in Phase 3)
• Eylea decline stabilizes or Eylea HD maintains meaningful share

...then 18x on $41 EPS is demonstrably cheap. Dupixent alone, at $14B revenue and growing 20%, on a standalone basis would command $75-100B in enterprise value — roughly equal to REGN's entire current market cap.

If you believe the Eylea decline accelerates and COPD disappoints commercially, the EPV and PEG methods may be right: $389-$317 range as a worst case.

April 29 begins to answer which scenario is unfolding.

Explore Regeneron's Valuation Further

The DCF Calculator lets you model Regeneron under different COPD-ramp scenarios — set EPS at $41.47, growth rate at -2.6% (current Eylea-drag trajectory) versus 12% (COPD adoption scenario), and observe how the intrinsic value range shifts.

The P/E Ratio Calculator lets you explore what REGN is worth at different multiple expansions — from the current 18x toward 25x (biotech compounder median) or 35x (sector median) on trailing EPS $41.47 and forward EPS $40.39.

The EV/EBITDA Calculator lets you see the current 12.69x EV/EBITDA against REGN's EBITDA per share of $56 — and compare that to the sector median of 28x to understand the source of the screener's MoS.

The Equity Rank screener shows REGN's full profile — Overall Score 72.9, Risk Score 26.5, Combined MoS +51.2%, Stability 82.3 — alongside all 800 scored equities.

This article is for informational and educational purposes only. It does not constitute financial advice or a recommendation to purchase or sell Regeneron Pharmaceuticals Inc (REGN) shares or any other security. All scores, margin of safety estimates, and fair value outputs are model-based computations subject to significant estimation uncertainty. The consensus fair value of $1,193 is derived from applying Biotechnology sector median multiples to REGN's trailing fundamentals; results reflect sector comparison, not a discounted cash flow projection of Dupixent-specific revenue. Negative MoS methods (EPV -91.7%, PEG -135.7%, DDM -244.4%, Graham -40.8%) reflect the limitations of backward-looking or income-based valuation for a company in an active franchise transition. Key risks include accelerated Eylea biosimilar erosion, slower-than-expected COPD commercial uptake, pipeline setbacks, and the concentration risk from Dupixent representing the majority of company revenue. EPS growth has been negative for five consecutive years on a trailing basis. Past performance does not guarantee future results. All investments involve risk, including loss of principal. Equity Rank is not a registered investment adviser. Always conduct your own due diligence and consult a qualified financial adviser before making investment decisions.